No Data
DWTI signs a collaborative research agreement with Nagoya Universities for the creation of schizophrenia treatment drugs.
DWTI <4576.T> announced on the 27th that it has signed a collaborative research agreement with Nagoya Universities to create innovative treatments for schizophrenia. Schizophrenia is a severe mental disorder that affects about 1% of the population, characterized by positive symptoms such as hallucinations and delusions, negative symptoms like a decrease in motivation, and cognitive dysfunction. In this collaborative research, the company's developed low molecular compounds will be utilized, and Professor Norio Ozaki, a specially appointed professor in the Department of Psychiatry at Nagoya University's Graduate School of Medicine, will be involved, along with AMED (Japan Agency for Medical Research and Development).
A steady and resilient U.S. Stocks market is providing support.
[Global Strategy for Emerging Markets] Today's emerging markets are expected to have a steady performance. Yesterday, on the 25th, the Dow Inc in the US stock market rose by 4.18 dollars (+0.01%) to 42,587.50 dollars, marking a slight increase for three consecutive days. The buying was supported by President Trump's suggestion of a flexible stance regarding 'reciprocal tariffs'. On the other hand, due to the deterioration in the consumer confidence Index ETF, concerns over economic slowdown caused the market to temporarily decline, but a drop in long-term interest rates supported the market, allowing it to recover into positive territory. Today's emerging markets are favored for buying.
D. Western Therapeutics Institute: Confirmation
D. Western Therapeutics Institute: Financial Report - 27th Term (2024/01/01 - 2024/12/31)
Individual stock information.
DWTI<4576.T> rebounded sharply. On the 18th, the company announced that it received notification from its licensing partner Kowa (Nagoya) that the administration to subjects in the Global Phase 3 clinical trial of the eye drop "K-321," which contains the active ingredient Rhok kinase inhibitor "Ripassizil hydrochloride hydrate," has been completed. Follow-up observations for the subjects are expected to be completed by the end of October. Trenders<6069.T> also rebounded. zenpl, a company engaged in planning, producing, and managing various events.
Earlier session / Active stocks and traded stocks [Active stocks and traded stocks]
*Daisue Construction <1814> 1962 +157 viewed as a Buy due to a significant Shareholding. *Tanseisha <9743> 1116 +66 continues to be positively received for its forecast of double-digit profit growth and planned dividend increase. *Yamashin Filter <6240> 631 +31 also has pointers such as the quarterly report. *Taiyo Yuden <6976> 2673 +131 is particularly lacking in materials, making short covering a dominant trend. *IHI <7013> 11790 +520 expansion in private aviation engine Components.